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BACKGROUND: Cancer incidence is increasing in the United Kingdom, as well as on a global basis. Biochemical parameters, such as
C-reactive protein and albumin (combined to form the modified Glasgow Prognostic Score, mGPS), alkaline phosphatase (Alk phos),
g-glutamyl transferase (GGT) and serum calcium have been reported to be associated with cancer and non-cancer mortality.
Therefore, to definitively examine the interrelationships between the above biochemical parameters, the mGPS and the presence of
cancer, the Glasgow Inflammation Outcome Study was undertaken. The aim of this initial study was to examine the effect of cancer
on markers of systemic inflammation induced by the liver (mGPS) and on levels of routine biochemical parameters.
METHODS: Patients (n¼223303) who had a single incidental sample taken for C-reactive protein, albumin, calcium and serum liver
function tests where available, between 2000 and 2008 were studied. Those with a pathological diagnosis of cancer (n¼22715)
were identified. The mGPS was constructed and liver function tests classified in accordance with the local reference ranges.
RESULTS: Patients with cancer had higher C-reactive protein and lower albumin levels (and thus a higher mGPS), higher adjusted
calcium, Alk phos and GGT levels, but lower aspartate transaminase (AST) and alanine transaminase (ALT) levels (all Po0.001).
The strongest associations (Spearman’s correlation X0.3) in both the non-cancer and cancer groups were found between albumin,
C-reactive protein and Alk phos, AST and ALT, AST and GGT and ALT and GGT (all Po0.001). On multivariate analysis, the
associations with the presence of cancer remained with age, deprivation, C-reactive protein, albumin, adjusted calcium, Alk phos and
GGT (all Po0.01). Patients following a diagnosis of cancer had lower albumin levels and thus higher mGPS (all Po0.001). Also, post-
diagnosis patients were more likely to have lower adjusted calcium, bilirubin, Alk Phos, AST, ALT and GGT levels (all Po0.05). When
the cancer diagnoses were ranked from those with the lowest proportion of mGPS 1 or 2 to those with the highest, the percentage
of cases with a mGPS of 1 or 2 ranged from 21% in breast cancer to 46% in prostate cancer and to 68% in pulmonary cancer.
Compared with breast cancer the mGPS was significantly higher in those diagnosed with dermatological, bladder, endocrinological,
gynaecological, prostate, musculoskeletal, gastroesophageal, haematological, renal, colorectal, head and neck, pancreaticobiliary and
pulmonary cancers (all Po0.001).
CONCLUSION: The results of the present study indicate that the systemic inflammatory response is common in a large patient cohort,
increased by the presence of cancer and associated with the perturbation of a number of biochemical parameters previously
reported to be associated with mortality. There is a striking parallel between the proportions of cases with a mGPS of 1 or 2 and
reported survival rates in these tumours.
British Journal of Cancer (2010) 103, 870–876. doi:10.1038/sj.bjc.6605855 www.bjcancer.com
Published online 17 August 2010
& 2010 Cancer Research UK
Keywords: C-reactive protein; albumin; adjusted calcium; liver function tests
                                                                            
Cancer incidence is increasing in the United Kingdom, as well as
on a global basis (Boyle and Levin, 2008). Over one in three people
in the United Kingdom will develop cancer during their lifetime
with around 150000 people dying each year as a consequence
(Cancer Research UK, 2007, 2008). Such a burden of disease
accounts for a significant proportion of annual healthcare
spending in the United Kingdom, the United States and worldwide
(Bosanquet and Sikora, 2004; Boyle and Levin, 2008).
In the West of Scotland there has been a longstanding interest in
the role of the systemic inflammatory response in determining
outcome in cancer (McMillan, 2008, 2009; Roxburgh and
McMillan, 2010). Although it is recognized that the development
of cancer has a genetic basis, there is increasing evidence that host
inflammatory responses have a pivotal role in the development
and progression of cancer (Balkwill and Mantovani, 2001;
Coussens and Werb, 2002; Mantovani et al, 2008; McDonald
et al, 2009; Colotta et al, 2009). This is consistent with the
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shypothesis that chronic exposure to inflammatory processes,
either through infection, social conditions or lifestyle, enhances
the ageing process (Finch and Crimmins, 2004).
Recently, the presence of a systemic inflammatory response, as
evidenced by an elevated C-reactive protein concentration sampled
incidentally in a large hospital-based cohort, was associated with a
shorter duration of cancer and non-cancer survival (Marsik et al,
2008). Goldwasser and Feldman (1997) reported a similar relation-
ship in a systematic review of the prognostic value of albumin.
These acute phase proteins, produced exclusively in the liver, have
been shown to be a major factor in the progressive nutritional
and functional decline of patients with cancer (McMillan, 2008).
Also, C-reactive protein and albumin concentrations have been
combined to form the modified Glasgow Prognostic Score (mGPS)
and have been reported to be independently associated with
reduced survival in patients with a variety of operable (Roxburgh
and McMillan, 2010) and inoperable cancers (McMillan, 2009).
It is also of interest that liver function tests, such as bilirubin
(Temme et al, 2001), alkaline phosphatase (Alk phos) (Tonelli
et al, 2009) and g-glutamyl transferase (GGT) (Kazemi-Shirazi
et al, 2007), as well as serum calcium (Leifsson and Ahren, 1996),
have also been reported to predict cancer and non-cancer
outcomes. There is also some evidence that liver function tests
are altered as part of the systemic inflammatory response in
patients with lung and gastrointestinal cancer (Brown et al, 2007;
Roxburgh et al, 2009).
Therefore, to definitively examine the interrelationships between
the above biochemical parameters, the mGPS and the presence of
cancer the Glasgow Inflammation Outcome Study was undertaken.
The aim of this initial study was to examine the effect of cancer on
markers of systemic inflammation induced by the liver (mGPS)
and on levels of routine biochemical parameters (bilirubin, Alk
phos, aspartate transaminase (AST), alanine transaminase (ALT),
GGT and adjusted calcium).
MATERIALS AND METHODS
Study design
This cohort includes patients who have had a single sample taken
for C-reactive protein, albumin and calcium between the first of
January 2000 and the first of November 2008 in the North
of Glasgow. The samples were taken incidentally and if more than
one set of measurements were available for a given patient then
only the initial set was used. Where available, serum liver function
tests, including bilirubin, Alk phos, AST, ALT and GGT were
recorded. Patients were excluded if they did not have a complete
set of identifying details (name, gender, date of birth and hospital
number).
All patient records fulfilling these criteria were then cross
referenced with the local pathology database to identify those in
whom a tissue diagnosis of cancer had been made either before or
after their initial blood sample. Systematized Nomenclature of
Medicine – Clinical Terms (SNOMED CT) codes, which share
certain codes with the International Classification of Diseases,
contained in the pathology database were used to identify the site
and type of tumour in those with a tissue diagnosis of cancer.
Patients in the cohort were then grouped into those with a
pathological diagnosis of cancer and those without. The cancer
groups were then grouped into those patients with a clear primary
cancer diagnosis, those with multiple tumours or those with no
clear indication of the primary tumour site. For the purpose of
analysis, cancers were grouped according to tumour site; bladder,
breast, colorectal, dermatological, endocrinological, gastroesopha-
geal, gynaecological, haematological, head and neck, hepatocel-
lular, musculoskeletal and soft tissue, pancreaticobiliary,
pulmonary, prostatic, renal and testicular.
The study was approved by the Research Ethics Committee,
North Glasgow NHS Trust.
Methods
Patients with routine laboratory measurements of C-reactive
protein, albumin and calcium were obtained by systematically
searching the North Glasgow biochemical database system. The
limit of detection of C-reactive protein was a concentration of less
than 5mgl
 1. The mGPS was constructed as follows; patients with
both an elevated C-reactive protein (410mgl
 1) and hypoalbu-
minaemia (o35gl
 1) were allocated a score of 2; patients in whom
C-reactive protein was elevated (410mgl
 1) were allocated a
score of 1 and those with both a normal C-reactive protein and
albumin were allocated a score of 0 (McMillan et al, 2007). The
rationale and basis of the mGPS has been previously described
(McMillan, 2008). Serum C-reactive protein, albumin and liver
function tests, including bilirubin, Alk phos, AST, ALT and GGT,
as well as calcium adjusted for albumin (Ashby et al, 1986), were
classified in accordance with the NHS Greater Glasgow and Clyde
reference ranges (shown in Table 2). These analytes were measured
using identical standard operating procedures on identical
automated platforms using reagents from the same manufacturer
(Abbot diagnostics). Analysis was carried out in three linked
laboratories in the North of Glasgow that take part in external
quality assurance schemes for routine biochemical analysis. All
samples were refrigerated, as stable for a number of days in these
conditions, and analyzed within 6h.
Deprivation was measured with the Scottish Index of Multiple
Deprivation 2006. The Scottish Index of Multiple Deprivation 2006
classification of deprivation is based on an individual’s postcode
and is derived from the measurements of 37 indicators across
seven domains including income, employment, education, hous-
ing, health, crime and geographical access. The Scottish Index of
Multiple Deprivation 2006 is the recommended method for the
measurement of deprivation in Scotland by the Information
Services Division on behalf of NHS Scotland and the Scottish
Government Department of Health (Bishop et al, 2004).
SNOMED CT codes were used to identify the site and type of
tumour in those with a tissue diagnosis of cancer. Each pathology
sample had two SNOMED CT codes, one for type of tumour
(morphology) and one for site of tumour (topography). Examples
of SNOMED CT cancer morphology codes, of which there are over
400, include metastatic carcinoma (M80106), large-cell carcinoma
(M80123), small-cell carcinoma (M80413-M80416), squamous-cell
carcinoma (M80703-M80763), adenocarcinoma (M81402-M81406),
cholangiocarcinoma (M81603), renal cell carcinoma (M83123-
M83126), intraductal carcinoma (M85002-M85003), malignant
melanoma (M87202-M87433), mesothelioma (M90501-M90503),
lymphoma (M95903-M97003) and leukaemia (M98003-M99403).
Examples of SNOMED CT topography codes include bladder
(T74000-T74400), breast (T04000-T04400), colorectal (colon
T67000-T67995, rectum T68000-T68200, anus T69000-T69200)
dermatological (T02100-02870), endocrine (adrenal T93000-
T93100, thyroid T96000-T97800), gastroesophageal (oesophagus
T62000-T62910, stomach T63000-T63700), gynaecological (uterus
with or without cervix T82000-T82900, uterus and ovaries T82920-
T82922, cervix T83000-T83300, endometrium T84000-T85000,
ovary T86920-T87800), haematological (bone marrow T06000-
T06600, lymph node T08000-T09600), head and neck (upper
respiratory tract T21000-T24920, mouth and salivary glands
T51000-T55550, pharynx T60000-T61300), liver (T56000-T56020),
musculoskeletal and soft tissue (skeletal bone T10000-T12720,
skeletal muscle T13000) pancreaticobiliary (gallbladder T57000,
bile duct T57600-T58500, pancreas and ampulla T58700-T59300)
pulmonary(T26000-T29900), prostatic (T77000-T77350), renal
(T71000-T72000) testicular (T78000-T78020). The combination of
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sSNOMED CT morphology and topography codes were used to
identify the tumour type and site.
Statistics
The relationships between patient demographics, the presence of
cancer, biochemical parameters, the mGPS, tumour site and other
biochemical parameters were analzsed using the Pearson’s w
2-test
(linear by linear association). Spearman’s rank correlation was
used to measure the strength of the relationship between age and
biochemical parameters and the interrelationships between
biochemical parameters. The relationship between the presence
of cancer and patient demographics and biochemical parameters
was examined using binary logistic regression analysis; only
patients who had a diagnosis of cancer made within 2 years
following their blood test were included in this analysis. This was
based on the premise that this group of patients were likely to have
had an ongoing malignant process at the time of blood sampling.
Analysis was performed using SPSS software (SPSS, Chicago,
IL, USA).
RESULTS
In total 223303 patients were studied. The majority, 144900 (65%),
were under 65 years of age. There were 120115 (54%) females and
103188 (46%) males. Of those patients with an identifiable
postcode (86%), the majorities were from the Greater Glasgow
area (88%). In this cohort, when measured by the Scottish Index
of Multiple Deprivation 2006, 14% of cases were from affluent
areas (least deprived quintile of the Scottish population) and 45%
from deprived areas (most deprived quintile of the Scottish
population).
The demographics of non-cancer and cancer patients are shown
in Table 1. Patients with cancer, when compared with those
without a diagnosis of cancer were older and more likely to be
female (Po0.001). The cancer group had a higher proportion of
cases from less deprived areas than those in the non-cancer group
(Po0.001).
Of 22715 with a diagnoses of cancer 19476 (86%) had a single
primary tumour, whereas 1299 (6%) had multiple malignancies. In
1940 (8%) cases SNOWMED CT codes gave no definitive
indication of the primary site of malignancy. Examples of this
include: 1497 cases were SNOWMED CT codes stated lung
carcinoma, lung adenocarcinoma or lung metastatic carcinoma;
269 cases were SNOWMED CT codes stated liver carcinoma, liver
adenocarcinoma or liver metastatic carcinoma; 209 cases had
SNOWMED CT codes stated lymph node carcinoma, lymph
node adenocarcinoma or lymph node metastatic carcinoma and
160 cases had SNOWMED CT codes stating metastatic carcinoma
at other sites.
When the cancer group was categorized (n¼22715) into
different tumour sites the following main groups were observed;
bladder (n¼939, 4%), breast (n¼3849, 17%), colorectal
(n¼1899, 8%), dermatological (n¼4907, 22%), endocrinolo-
gical (n¼303, 1%), gastroesophageal (n¼1018, 5%), gynaecolo-
gical (n¼1136, 5%), haematological (n¼1165, 5%), head and
neck (n¼610, 3%), hepatocellular (n¼55, 0%), musculoskeletal
and soft tissue (n¼164, 1%), pancreaticobiliary (n¼456, 2%),
prostate (n¼957, 4%), pulmonary (n¼1393, 6%), renal (n¼527,
2%) and testicular (n¼97, 1%).
The patient biochemical parameters in the non-cancer and
cancer groups are shown in Table 2. There were higher circulating
concentrations of C-reactive protein and lower albumin levels
(and thus a higher proportion of mGPS 1 or 2), in those patients
with cancer (all Po0.001). Patients in the cancer group were also
found to have lower AST and ALT levels, but higher adjusted
calcium, Alk phos and GGT levels compared with the non-cancer
cohort (all Po0.001).
The interrelationships between age and biochemical parameters
in the non-cancer and cancer cohorts are shown in Tables 3 and 4.
In the non-cancer cohort age was significantly associated with all
Table 1 Patient demographics in the non-cancer and cancer groups in
the Glasgow Inflammation Outcome Study
Non-cancer
n (%) 200588
Cancer
n (%) 22715 P-value
Age (years)
o65 135531 (67) 9369 (41)
65–74 31593 (16) 6412 (28)
X75 33464 (17) 6934 (31) o0.001
Sex
Male 93313 (46) 9875 (43)
Female 107275 (54) 12840 (57) o0.001
SIMD 2006
1 (Most deprived) 77448 (45) 8844 (42)
2 30850 (18) 3872 (18)
3 21148 (12) 2771 (13)
4 18693 (11) 2578 (12)
5 (Least deprived) 22902 (14) 3233 (15) o0.001
Table 2 The relationship between the presence of cancer, biochemical
parameters and the mGPS in the Glasgow Inflammation Outcome Study
Non-cancer
n (%) 200588
Cancer
n (%) 22715 P-value
C-reactive protein
p10mgl
 1 122317 (61) 12050 (53)
410mgl
 1 78271 (39) 10665 (47) o0.001
Albumin
o35gl
 1 27515 (14) 4275 (19)
X35gl
 1 173073 (86) 18440 (81) o0.001
mGPS
0 122317 (61) 12050 (53)
1 56357 (28) 7033 (31)
2 21914 (11) 3632 (16) o0.001
Adjusted calcium
o2.10mmoll
 1 4963 (3) 577 (2)
2.10–2.60mmoll
 1 191429 (95) 21323 (94)
42.60mmoll
 1 4196 (2) 815 (4) o0.001
Bilirubin
o20mmoll
 1 170447 (88) 19322 (88)
X20mmoll
 1 24258 (12) 2593 (12) 0.008
Alkaline phosphatase
o80Ul
 1 28168 (14) 2463 (11)
80–280Ul
 1 148245 (74) 16626 (73)
4280Ul
 1 23954 (12) 3603 (16) o0.001
Aspartate transaminase
o40Ul
 1 162269 (84) 18676 (86)
X40Ul
 1 30531 (16) 3129 (14) o0.001
Alanine transaminase
o50Ul
 1 144468 (88) 15872 (90)
X50Ul
 1 19043 (12) 1740 (10) o0.001
g-Glutamyl transferase
Mo70Ul
 1,F o40Ul
 1 145658 (75) 15689 (71)
MX70Ul
 1,F X40Ul
 1 49393 (25) 6325 (29) o0.001
Abbreviation: mGPS¼modified Glasgow Prognostic Score.
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sthe biochemical parameters (all Po0.001) (Table 3). Similarly,
all biochemical parameters were significantly associated with
each other (all Po0.001). In the non-cancer cohort the
strongest associations (Spearman’s correlation X0.3) were bet-
ween C-reactive protein and albumin, C-reactive protein and
Alk phos, AST and ALT, AST and GGT and ALT and GGT.
There were similar interrelationships in the cancer cohort
(Table 4) with the strongest associations (Spearman’s correlation
X0.3) existing between C-reactive protein and albumin, C-reactive
protein and Alk phos, bilirubin and AST, Alk phos and GGT, AST
and ALT, AST and GGT and ALT and GGT.
The temporal relationships between the date of blood samples,
biochemical parameters and the mGPS in the cancer group are
shown in Table 5. To give a clearer indication of the alterations
that occur in biochemical parameters surrounding the diagnosis of
Table 3 The relationship between biochemical parameters in the non-cancer group of the Glasgow Inflammation Outcome Study
n¼200588
C-reactive
protein Albumin
Adjusted
calcium Bilirubin
Alkaline
phosphatase
Aspartate
transaminase
Alanine
transaminase
c-Glutamyl
transferase
Age 0.199***  0.286*** 0.052*** 0.099*** 0.177*** 0.078***  0.047*** 0.148***
C-reactive protein  0.362***  0.108*** 0.167*** 0.320*** 0.103*** 0.040*** 0.193***
Albumin  0.060*** 0.040*** 0.022*** 0.009*** 0.072***  0.116***
Adjusted calcium  0.077***  0.147***  0.081***  0.028*** 0.077***
Bilirubin 0.143*** 0.297*** 0.216*** 0.169***
Alkaline phosphatase 0.225*** 0.152*** 0.243***
Aspartate transaminase 0.736*** 0.437***
Alanine transaminase 0.550***
***Po0.001.
Table 4 The relationship between biochemical parameters in the cancer group of the Glasgow Inflammation Outcome Study
n¼22715
C-reactive
protein Albumin
Adjusted
calcium Bilirubin
Alkaline
phosphatase
Aspartate
transaminase
Alanine
transaminase
c-Glutamyl
transferase
Age 0.103***  0.203*** 0.024*** 0.127*** 0.079*** 0.020**  0.162***  0.062***
C-reactive protein  0.439***  0.078*** 0.166*** 0.308*** 0.104*** 0.034*** 0.239***
Albumin  0.086*** 0.004 0.028*** 0.007 0.073***  0.123***
Adjusted calcium  0.095***  0.087***  0.053***  0.013 0.106***
Bilirubin 0.166*** 0.307*** 0.225*** 0.177***
Alkaline phosphatase 0.253*** 0.213*** 0.346***
Aspartate transaminase 0.720*** 0.403***
Alanine transaminase 0.505***
***Po0.001.
Table 5 The relationship between time of diagnosis, biochemical
parameters and the mGPS in the cancer group of the Glasgow
Inflammation Outcome Study
Pre-diagnosis
n (%) 8083
Post-diagnosis
n (%) 5971 P-value
Age (years)
o65 3516 (43) 2690 (45)
65–74 2413 (30) 1626 (27)
X75 2154 (27) 1655 (28) 0.732
Sex
Male 3806 (47) 2482 (42)
Female 4277 (53) 3489 (58) o0.001
SIMD 2006
1 (Most deprived) 3042 (40) 2011 (37)
2 1428 (19) 1003 (18)
3 1080 (14) 802 (15)
4 958 (12) 724 (13)
5 (Least deprived) 1140 (15) 951 (17) o0.001
C-reactive protein
p10mgl
 1 4082 (51) 2963 (50)
410mgl
 1 4001 (49) 3008 (50) 0.304
Albumin
o35gl
 1 1566 (19) 1545 (26)
X35gl
 1 6517 (81) 4426 (74) o0.001
mGPS
0 4082 (50) 2963 (50)
1 2666 (33) 1643 (27)
2 1335 (17) 1365 (23) o0.001
Adjusted calcium
o2.10mmoll
 1 183 (2) 151 (3)
2.10–2.60 7501 (93) 5614 (94)
42.60mmoll
 1 399 (5) 206 (3) o0.001
Bilirubin
o20mmoll
 1 6844 (87) 5163 (90)
Table 5 (Continued)
Pre-diagnosis
n (%) 8083
Post-diagnosis
n (%) 5971 P-value
X20mmoll
 1 994 (13) 587 (10) o0.001
Alkaline phosphatase
o80Ul
 1 788 (10) 743 (12)
80–280Ul
 1 5805 (72) 4324 (73)
4280Ul
 1 1482 (18) 898 (15) 0.003
Aspartate transaminase
o40Ul
 1 6614 (85) 4941 (86)
X40Ul
 1 1175 (15) 788 (14) 0.030
Alanine transaminase
o50Ul
 1 5729 (89) 4215 (90)
X50Ul
 1 734 (11) 450 (10) 0.004
g-Glutamyl transferase
Mo70U/l, Fo40Ul
 1 5440 (69) 4100 (71)
MX70U/l, FX40Ul
 1 2432 (31) 1667 (29) 0.012
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scancer, only those patients who were diagnosed within 2 years of
their blood sample being analyzed were included in the analysis,
pre-diagnosis (n¼8083) and post diagnosis (n¼5971). Compared
with those patients who had pre-diagnosis levels, post-diagnosis
patients were more likely to be female and affluent (all Po0.001).
Patients following a diagnosis of cancer had lower albumin levels
and thus higher mGPS (all Po0.001). Also, post-diagnosis patients
were more likely to have lower adjusted calcium, bilirubin, Alk
Phos, AST, ALT and GGT levels (all Po0.05).
The relationship between patient demographics, biochemical
parameters and the absence (n¼200588) or presence (n¼8083)
of cancer within 2 year-pre-diagnosis group is shown in Table 6.
On univariate analysis, those over 65 years of age and living in
least deprived areas were more likely to have cancer (all Po0.001).
Patients with an elevated C-reactive protein, adjusted calcium,
Alk phos and GGT levels or low albumin levels were more likely to
have cancer (all Po0.001). On multivariate analysis, these
associations with the presence of cancer persisted in age, depri-
vation, C-reactive protein, albumin, adjusted calcium, Alk phos
and GGT (all Po0.01).
The relationships between the mGPS and tumour site in the
2-year pre-diagnosis group is shown in cancers with more than
50 cases in Table 7. The cancers are ranked from those with the
highest proportion of mGPS 0 to those with the lowest.
The percentage of cases with a mGPS of 1 or 2 ranges from 21%
in breast cancer, to 46% in prostate cancer and to 68% in
pulmonary cancer. Compared with breast cancer the mGPS was
significantly higher in dermatological, bladder, endocrinological,
Table 6 The relationship between patient demographics, biochemical parameters and the presence of cancer in the Glasgow Inflammation
Outcome Study
Univariate analysis Multivariate analysis
OR 95% CI P-value OR 95% CI P-value
Age
o65/ 1 o0.001 1 o0.001
65–74 2.94 2.79–3.12 o0.001 2.60 2.46–2.75 o0.001
X75 2.48 2.35–2.62 o0.001 2.17 2.05–2.30 o0.001
Sex
Male 1 0.317
Female 0.98 0.94–1.02 0.317
SIMD
1 (Most deprived) 1 o0.001 1 o0.001
2 1.18 1.11–1.26 o0.001 1.16 1.09–1.24 o0.001
3 1.30 1.21–1.40 o0.001 1.32 1.22–1.42 o0.001
4 1.31 1.21–1.41 o0.001 1.36 1.26–1.46 o0.001
5 (Least deprived) 1.27 1.18–1.36 o0.001 1.27 1.18–1.36 o0.001
C-reactive protein
p10mgl
 1 1 o0.001 1 o0.001
410mgl
 1 1.53 1.47–1.60 o0.001 1.22 1.16–1.28 o0.001
Albumin
o35gl
 1 1.51 1.43–1.60 o0.001 1.11 1.04–1.19 0.002
X35gl
 1 1 o0.001 1 0.002
Adjusted calcium
o2.10mmoll
 1 0.94 0.81–1.09 0.425
2.10–2.60mmoll
 1 1 o0.001 o0.001
42.60mmoll
 1 2.43 2.18–2.70 o0.001 1.90 1.70–2.21 o0.001
Bilirubin
o20mmoll
 1 1 0.558
X20mmoll
 1 1.02 0.95–1.09 0.558
Alkaline phosphatase
o80Ul
 1 0.71 0.66–0.77 o0.001 0.81 0.75–0.87 o0.001
80–280Ul
 1 1 o0.001 1 o0.001
4280Ul
 1 1.58 1.49–1.68 o0.001 1.30 1.22–1.39 o0.001
Aspartate transaminase
o40Ul
 1 1 0.075
X40Ul
 1 0.94 0.89–1.01 0.075
Alanine transaminase
o50Ul
 1 1 0.477
X50Ul
 1 0.97 0.90–1.05 0.477
g-Glutamyl transferase
Mo70Ul
 1,F o40Ul
 1 1 o0.001 1
MX70Ul
 1,F X40Ul
 1 1.32 1.26–1.38 o0.001 1.09 1.03–1.15 0.003
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sgynaecological, prostate, musculoskeletal, gastroesophageal,
haematological, renal, colorectal, head and neck, pancreati-
cobiliary and pulmonary cancers (all Po0.001).
DISCUSSION
The initial results of the Glasgow Inflammation Outcome Study
show that the presence of a systemic inflammatory response, as
evidenced by an elevated C-reactive protein concentration
(410mgl
 1), was present in 40% and hypoalbuminaemia
(o35gl
 1) was present in 14% of 223303 patients who were
incidentally sampled. Adjusted calcium was elevated in 2.2% (1.8%
unadjusted), Alk phos was elevated in 12%, ALT was elevated in
11% and GGT was elevated in 26% of patients studied.
These results are consistent with previous studies including an
Austrian cohort of approximately 280000 patients, in whom 35%
had an elevated C-reactive protein concentration (Marsik et al,
2008) and 13% had hypoalbuminaemia (Grimm et al, 2009). They
also reported that 33% had an elevated GGT concentration
(Kazemi-Shirazi et al, 2007). In a Swedish population-based
cohort of 33346 patients, 1% were found to have an elevated
unadjusted serum calcium (Leifsson and Ahren, 1996). In a North
American cohort of 18835 patients approximately 9% had an
elevated Alk phos (Tonelli et al, 2009). Another population-based
cohort from the United States of 14950 patients reported an
elevated ALT level in 14% of patients (Ruhl and Everhart, 2009).
Therefore, the results of the present study are similar to those
previously reported in other large cohort studies.
In the present study there were more females in the cohort as a
whole, more females in the cancer group and more females had
measurements taken after cancer diagnosis. However, gender was
not significantly associated with the presence of cancer. The
present study shows that when compared with non-cancer, the
presence of cancer was associated with a significantly higher
proportion of cases with an elevated C-reactive protein
(410mgl
 1,4 7vs 39%) and lower albumin (o35gl
 1,1 9vs
14%) concentrations, higher adjusted calcium (42.60mmoll
 1,4
vs 2%), Alk phos (4280Ul
 1,1 6vs 12%) and GGT (X40Ul
 1
in females, X70Ul
 1 in males, 29 vs 25%) and lower ALT levels
(X50Ul
 1,1 0vs 12%). Furthermore, when samples taken
following a diagnosis of cancer were compared with those taken
before a diagnosis of cancer the proportion of cases with albumin
(X35gl
 1,7 4vs 81%) adjusted calcium (42.60mmoll
 1,3vs
5%), Alk phos (4280Ul
 1,1 5vs 18%), ALT (X50Ul
 1,1 0vs
11%). and GGT (X40Ul
 1, in females and X70Ul
 1 in males
29 vs 31%) levels were all lower. When these biochemical para-
meters, together with bilirubin and ALT, were regressed against
the presence of cancer, C-reactive protein, albumin, adjusted
calcium, Alk phos and GGT were all shown to be independently
associated with the presence of cancer. These results would suggest
that the presence of cancer influences a number of biochemical
parameters that have been previously associated with all cause
mortality (Leifsson and Ahren, 1996; Kazemi-Shirazi et al, 2007;
Marsik et al, 2008; Grimm et al, 2009, Tonelli et al, 2009).
The present study also showed that all these biochemical
parameters were significantly associated. In particular, C-reactive
protein was associated with albumin and Alk phos and GGT
associated with AST and ALT in both cancer and non-cancer
cohorts. Recently the combination of C-reactive protein and
albumin, termed the mGPS, was shown to be associated in a
similar manner in patients with lung cancer (Brown et al, 2007)
and predict cancer-specific survival in a number of operable
(Roxburgh and McMillan, 2010) and inoperable cancers (McMillan,
2009). These results raise the question of whether the above
reported association of these biochemical parameters and all cause
mortality are indeed independent of each of other. Further studies
using this cohort will aim to address this question.
In the present study the proportions of mGPS 1 or 2 were greater
following a diagnosis of cancer. This appears to be secondary to a
reduction in albumin that may be secondary to a number of
factors, including operative management, adjuvant oncological
therapies or tumour progression, a pattern recognized in previous
studies within specific tumour types (McMillan et al, 2003;
Jamieson et al, 2005). It is interesting that in patients who had
blood tests taken following a diagnosis of cancer, adjusted calcium,
bilirubin and Alk phos, AST, ALT and GGT levels were all more
likely to be within normal limits. The reasons for this are unclear
but it is possible that removal or oncological treatment of the
underlying malignant process in a proportion of these patients
may be responsible.
In the present study it was also of interest to note that, before
diagnosis, there were significant variations in the proportions of
cases with a mGPS of 1 or 2. Indeed, the proportion of patients
with an elevated mGPS varied from 21% in breast cancer, to 46%
in prostate cancer and to 68% in pulmonary cancer. There is a
striking similarity between the proportions of cases with a mGPS
of 1 or 2 and reported survival rates in these tumours (Cancer
Research UK, 2004). For example, the 5-year survival rate for
breast cancer is 77% and the proportion of patients in the present
study with a mGPS of 0 was 79%. In contrast the 5-year survival for
lung cancer is 6% and the proportion of patients in the present
study with a mGPS of 0 was 32%. These results may suggest that, in
addition to the mGPS having prognostic value within tumour types
(McMillan, 2009; Roxburgh and McMillan, 2010) it may also have
prognostic value across tumour types. Further work is required to
confirm this hypothesis.
The present cohort has a number of limitations. The patients
were selected on the basis that measurements of C-reactive protein,
albumin and calcium had been performed and were, therefore, not
necessarily representative of all non-cancer and cancer patients
treated in the North Glasgow area and, therefore, gives no
meaningful information on cancer prevalence. Furthermore,
sampling was incidental and not performed at a standard time
during the course of the disease in the cancer group. It is also
recognized that patients in both groups may have concurrent
morbidity causing a rise in their C-reactive protein and derange-
ment of their albumin and other biochemical parameters. As
inclusion in the cancer cohort was dependent on a pathological
diagnosis of cancer it is acknowledged that a small number in the
non-cancer group may have had a clinical diagnosis of malignancy.
Table 7 The relationship between tumour site and an inflammation-
based prognostic score (mGPS) in the Glasgow Inflammation Outcome
Study
mGPS n (%)
Tumour site Total N 012 P-value
a
Breast 1199 950 (79) 207 (17) 42 (4)
Dermatological 1126 693 (62) 310 (27) 123 (11) o0.001
Bladder 296 174 (59) 76 (26) 46 (15) o0.001
Endocrinological 145 84 (58) 41 (28) 20 (14) o0.001
Gynaecological 197 108 (55) 60 (30) 29 (15) o0.001
Prostate 267 145 (54) 91 (34) 31 (12) o0.001
Musculoskeletal 78 41 (53) 15 (19) 22 (28) o0.001
Gastroesophageal 503 249 (50) 162 (32) 92 (18) o0.001
Haematological 499 245 (49) 157 (32) 97 (19) o0.001
Renal 294 132 (45) 105 (36) 57 (19) o0.001
Colorectal 784 342 (44) 250 (32) 192 (24) o0.001
Head and neck 156 67 (43) 58 (37) 31 (20) o0.001
Pancreaticobiliary 321 122 (38) 101 (31) 98 (31) o0.001
Pulmonary 820 260 (32) 387 (47) 173 (21) o0.001
Abbreviation: mGPS¼modified Glasgow Prognostic Score.
aCompared with breast
cancer.
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important to link the present data with patient outcomes.
In summary, the results of the present study indicate that the
systemic inflammatory response is common in a large patient
cohort, increased by the presence of cancer and associated with the
perturbation of a number of biochemical parameters previously
reported to be associated with mortality. Taken together with the
myriad effects of the systemic inflammatory response on host
metabolism (Gabay and Kushner, 1999) these results have a
number of clinical implications particularly for clinical epidemio-
logical studies. Future studies should incorporate a measure of the
systemic inflammatory response, such as C-reactive protein or
the mGPS, in the study design, analysis and interpretation. This is
required to account for the likely confounding effect of this
response on the other measured variables and their relationship
with outcomes.
REFERENCES
Ashby JP, Wright DJ, Rinsler MG (1986) The adjusted serum calcium
concept – a reappraisal. Ann Clin Biochem 23: 533–537
Balkwill F, Mantovani A (2001) Inflammation and cancer: back to Virchow?
Lancet 357: 539–545
Bishop J, Clark D, Harris V, Stolkton, Sutton M (2004) Deprivation and
Urban Rural Measurements in ISD – Summary Report, 2004. ISD
Geography, Population, Census and Deprivation Group: Edinburgh
Bosanquet N, Sikora K (2004) The economics of cancer care in the UK.
Lancet Oncol 5: 568–574
Boyle P, Levin B (2008) World Cancer Report 2008. IARC Nonserial
Publication. World Health Organisation: Lyon
Brown DJ, Milroy R, Preston T, McMillan DC (2007) The relationship
between an inflammation-based prognostic score (Glasgow Prognostic
Score) and changes in serum biochemical variables in patients with
advanced lung and gastrointestinal cancer. J Clin Pathol 60: 705–708
Cancer Research UK (2004) CancerStats Monograph – Cancer Incidence,
Survival and Mortality in the UK and EU. Cancer Research UK: London,
UK. http://info.cancerresearchuk.org/cancerstats/faqs/index.htm
Cancer Research UK (2007) CancerStats Report – Mortality UK. Cancer
Research UK: London, UK. http://info.cancerresearchuk.org/cancerstats/
faqs/index.htm
Cancer Research UK (2008) CancerStats Report – Incidence UK. Cancer Research
UK: London, UK. http://info.cancerresearchuk.org/cancerstats/faqs/index.htm
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A (2009) Cancer-
related inflammation, the seventh hallmark of cancer: links to genetic
instability. Carcinogenisis 7: 1073–1081
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420: 860–867
Finch CE, Crimmins EM (2004) Inflammatory exposure and historical
changes in human life-spans. Science 305: 1736–1739
Gabay C, Kushner I (1999) Acute-phase proteins and other systemic
responses to inflammation. N Engl J Med 340: 448–454
Goldwasser P, Feldman J (1997) Association of serum albumin and
mortality risk. J Clin Epidemiol 50: 693–703
G r i m mG ,H a s l a c h e rH ,K a m p i t s c hT ,E n d l e rG ,M a r s i kC ,S c h i c k b a u e rT ,
Wagner O, Jilma B (2009) Sex differences in the association between
albumin and all-cause and vascular mortality. Eur J Clin Invest 39: 860–865
Jamieson NB, Glen P, McMillan DC, McKay CJ, Foulis AK, Carter R, Imrie
CW (2005) Systemic inflammatory response predicts outcome in patients
undergoing resection for ductal adenocarcinoma head of pancreas.
Br J Cancer 92: 21–23
Kazemi-Shirazi L, Endler G, Winkler S, Schickbauer T, Wagner OF, Marsik
C (2007) Gamma glutamyltransferase and long-term survival: is it just
the liver? Clin Chem 53: 940–946
Leifsson BG, Ahren B (1996) Serum calcium and survival in a large health
screening program. J Clin Endocrinol Metab 81: 2149–2153
Mantovani A, Romero P, Palucka A, Marincola F (2008) Tumour immunity:
effector response to tumour and role of the microenvironment.
Lancet 371: 771–783
Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, Joukhadar C,
Wagner OF, Endler G (2008) C-reactive protein and all-cause mortality in
a large hospital-based cohort. Clin Chem 54: 343–349
McDonald B, Spicer J, Giannais B, Fallavollita L, Brodt P, Ferri LE (2009)
Systemic inflammation increases cancer cell adhesion to hepatic
sinusoids by neutrophil mediated mechanisms. Int J Cancer 125:
1298–1305
McMillan DC (2008) An inflammation-based prognostic score and its role
in the nutrition-based management of patients with cancer. Proc Nutr
Soc 67: 257–262
McMillan DC (2009) Systemic inflammation, nutritional status and
survival in patients with cancer. Curr Opin Clin Nutr Metab Care 3:
223–226
McMillan DC, Canna K, McArdle CS (2003) The effect of deprivation and
the systemic inflammatory response on outcome following curative
resection for colorectal cancer. Br J Cancer 89: 612–614
McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS (2007)
Evaluation of an inflammation-based prognostic score (GPS) in patients
undergoing resection for colon and rectal cancer. Int J Colorectal Dis 22:
881–886
Roxburgh CS, Crozier JE, Maxwell F, Foulis AK, Brown J, McKee RF,
Anderson JH, Horgan PG, McMillan DC (2009) Comparison of tumour-
based (Petersen Index) and inflammation-based (Glasgow Prognostic
Score) scoring systems in patients undergoing curative resection for
colon cancer. Br J Cancer 100: 701–706
Roxburgh CS, McMillan DC (2010) Role of systemic inflammatory
response in predicting survival in patients with primary operable cancer.
Future Oncol 1: 149–163
Ruhl CE, Everhart JE (2009) Elevated serum alanine aminotransferase and
gamma-glutamyltransferase and mortality in the United States popula-
tion. Gastroenterology 136: 477–485
Temme EH, Zhang J, Schouten EG, Kesteloot H (2001) Serum bilirubin and
10-year mortality risk in a Belgian population. Cancer Causes Control 12:
887–894
Tonelli M, Curhan G, Pfeffer M, Sacks F, Thadhani R, Melamed ML, Wiebe
N, Muntner P (2009) Relation between alkaline phosphatase, serum
phosphate, and all-cause or cardiovascular mortality. Circulation 120:
1784–1792
Initial results of the glasgow inflammation outcome study
MJ Proctor et al
876
British Journal of Cancer (2010) 103(6), 870–876 & 2010 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s